|
KMID : 1216720100020020110
|
|
Korean Journal of Gynecologic Endocrinology
2010 Volume.2 No. 2 p.110 ~ p.116
|
|
|
The Effect of Combined Oral Contraceptives on Metabolic and Cardiovascular Parameters in Patients with Polycystic Ovary Syndrome
|
|
Lim Kyung-Jin
Jeon Young-Eun
Yang Hyo-In
Lee Kyung-Eun
Kim Hye-Yeon
Seo Seok-Kyo
Cho Si-Hyun
Choi Young-Sik
Lee Byung-Seok
|
|
|
Abstract
|
|
|
|
Objectives: To evaluate the effects of combined oral contraceptives (COC), containing 30 μg ethinyl estradiol (EE)/ 3 mg drospirenone (DRSP) on metabolic and cardiovascular parameters in women with polycystic ovary syndrome. Methods: Thirty patients diagnosed as PCOS according to Rotterdam criteria were included in this study. 30 μg EE/ 3 mg DRSP was taken for 6 months. Follicle stimulating hormone (FSH), leutinizing hormone (LH), LH/FSH ratio, E2, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride (TG), LDL/HDL ratio, atherogenic index of plasma (AIP), total testosterone, sex-hormone binding globulin (SHBG), free androgen index (FAI), 17 hydroxyprogesterone (17-OHP), dehydroepiandrosterone sulfate (DHEAS), fasting insulin, fasting glucose, homeostatis model assessment insulin resistance (HOMA-IR), homocysteine, and high-sensitivity C-reactive protein (hsCRP) were measured at baseline and at the end of treatment. Results: STherapy with 30 μg EE /3 mg DRSP significantly decreased LH/FSH ratio. The serum androgen levels including total testosterone, DHEAS, and 17 OHP decreased significantly and FAI was reduced significantly, accompanied by an increase of SHBG level. Total cholesterol, TG, LDL cholesterol, and HDL cholesterol increased significantly. The AIP and LDL/HDL ratio were not changed by COC treatment. HOMA IR, the glucose to insulin ratio and cardiovascular markers including hsCRP and homocysteine were not changed significantly. Conclusion: Treatment with 30 μg EE/3 mg DRSP in women with PCOS, without significant negative impact on cardiovascular and metabolic parameters, COC with 30 μg EE/3 mg DRSP appears to be an effective drug in women with PCOS.
|
|
|
KEYWORD
|
|
|
Drospirenone, Oral Contraceptives, Polycystic Ovary Syndrome
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|